Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess.
NCT ID: NCT06344650
Last Updated: 2024-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2023-04-30
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Pasireotide Lar Therapy on Bone Metabolism
NCT07179926
Evaluation of Somatostatin Receptors and GH Receptor Expression on Bone of Acromegalic Patients (ACRO-BONE)
NCT05819554
Randomized Study of Growth Hormone on Bone Mineral Density in Patients With Adult Onset Growth Hormone Deficiency
NCT00006394
Bone MicroArchitecture in Acromegaly
NCT03225040
Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly
NCT00004332
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CROSSOVER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sample
Collection of blood serum for molecular and biochemical tests
Radiological tests
Performance of radiological tests (DXA, VFA, TBS, BSi, HR-pQCT) and DXA morphometry
Questionnaires
Compilation of questionnaires (AcroQol, SF-36)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* availability to carry out outpatient checks
* ability to provide informed consent
Exclusion Criteria
* use of glucocorticoids (except those in use for replacement therapy)
* alcohol abuse
* exacerbation of chronic disease
* serious comorbidities (renal or hepatic failure, heart attack, stroke)
* terminally ill, prolonged immobilization (\>1 week)
* clinically evident fracture within the previous six months
* any other cause of secondary osteoporosis within the last five years
* any prolonged treatment with drugs with documented influence on bone metabolism during the previous 12 months, including treatment with antiresorptive or anabolic compounds for osteoporosis.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondazione Policlinico Universitario Campus Bio-Medico
OTHER
Istituto Auxologico Italiano
OTHER
IRCCS San Raffaele
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrea Giustina
Head of Endocrinology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Andrea Giustina
Milan, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RF-2021-12373584
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.